Comparative Pharmacology
Head-to-head clinical analysis: BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER versus TIMOLOL MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER versus TIMOLOL MALEATE.
BREVIBLOC DOUBLE STRENGTH IN PLASTIC CONTAINER vs TIMOLOL MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective beta-1 adrenergic receptor antagonist; reduces heart rate, myocardial contractility, and blood pressure by blocking catecholamine effects at beta-1 receptors.
Non-selective beta-adrenergic receptor antagonist (beta-blocker). Competitively blocks beta1 and beta2 receptors, reducing heart rate, myocardial contractility, and cardiac output. Also decreases aqueous humor production in the eye by blocking beta2 receptors on ciliary epithelium.
Intravenous: For stable patients, an initial loading dose of 500 mcg/kg/min over 1 minute followed by a maintenance infusion of 50 mcg/kg/min for 4 minutes; if response is inadequate, increase maintenance infusion to 100 mcg/kg/min and repeat loading dose after 10 minutes. Titrate in 50 mcg/kg/min increments up to 200 mcg/kg/min. For intraoperative and postoperative use, see full prescribing information.
Systemic: 1 drop of 0.25% or 0.5% solution in affected eye(s) twice daily. Additional indication: 0.5% gel-forming solution once daily. Oral: 10 mg twice daily, may increase to 20 mg twice daily if needed.
None Documented
None Documented
Terminal elimination half-life is approximately 9 minutes (range 8–10 minutes). Clinically, the half-life is consistent with rapid offset of effect upon discontinuation; steady state is achieved within 30 minutes of continuous infusion.
2-3 hours (terminal); prolonged in hepatic impairment
Primarily metabolized by red blood cell esterases; <1% excreted unchanged in urine. Elimination is not dependent on renal or hepatic function.
Renal: 20% unchanged; biliary/fecal: 80% as metabolites
Category C
Category A/B
Beta-Blocker
Beta-Blocker